D. E. Shaw & Co., Inc.
- SEC CIK
- 0001009207
- Latest filing
- Aug 14, 2026
VRDN holding history
Viridian Therapeutics, Inc. in every 13F filed by D. E. Shaw & Co., Inc., including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
VRDN overviewAll 13F holders of VRDNFull Q2 2026 holdings
- Shares (Q2 2026)
- 1,182,222
- Value
- $21.7M
- % of portfolio
- <0.1%
- Quarters held
- 14
- Since Q1 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2026 | 1,182,222 | $21.7M | <0.1% | −80,318−6.4% | Reduced | Holders |
| Q1 2026 | 1,262,540 | $24.7M | <0.1% | +261,823+26.2% | Added | Holders |
| Q4 2025 | 1,000,717 | $31.1M | <0.1% | +1,000,717 | New | Holders |
| Q2 2025 | 0 | $0 | 0.0% | −81,383−100.0% | Sold out | Holders |
| Q1 2025 | 81,383 | $1.10M | <0.1% | −360,687−81.6% | Reduced | Holders |
| Q4 2024 | 442,070 | $8.47M | <0.1% | +304,003+220.2% | Added | Holders |
| Q3 2024 | 138,067 | $3.14M | <0.1% | +138,067 | New | Holders |
| Q1 2023 | 0 | $0 | 0.0% | −338,167−100.0% | Sold out | Holders |
| Q4 2022 | 338,167 | $9.88M | <0.1% | −290,108−46.2% | Reduced | Holders |
| Q3 2022 | 628,275 | $12.9M | <0.1% | −130,853−17.2% | Reduced | Holders |
| Q2 2022 | 759,128 | $8.78M | <0.1% | −23,967−3.1% | Reduced | Holders |
| Q1 2022 | 783,095 | $14.5M | <0.1% | +18,482+2.4% | Added | Holders |
| Q4 2021 | 764,613 | $15.1M | <0.1% | +44,083+6.1% | Added | Holders |
| Q3 2021 | 720,530 | $11.9M | <0.1% | +1570.0% | Added | Holders |
| Q2 2021 | 720,373 | $13.2M | <0.1% | +531,861+282.1% | Added | Holders |
| Q1 2021 | 188,512 | $3.15M | <0.1% | – | – | Holders |
Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.